Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen
The predictivity of tumour size, oestrogen (ER) and progesterone (PgR) receptors, 3H-thymidine labelling index (TLI), c-erbB-2 and p27kip1 expression on clinical outcome was analysed on a consecutive series of 118 postmenopausal patients with ER-positive, node-positive tumours. All patients were tre...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2001-07, Vol.68 (2), p.101-110 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 110 |
|---|---|
| container_issue | 2 |
| container_start_page | 101 |
| container_title | Breast cancer research and treatment |
| container_volume | 68 |
| creator | SCARPI, Emanuela DE PAOLA, Franca SARTI, Manuela BAJORKO, Paola GRANATO, Anna Maria VOLPI, Annalisa NANNI, Oriana MALTONI, Roberta AMADORI, Dino |
| description | The predictivity of tumour size, oestrogen (ER) and progesterone (PgR) receptors, 3H-thymidine labelling index (TLI), c-erbB-2 and p27kip1 expression on clinical outcome was analysed on a consecutive series of 118 postmenopausal patients with ER-positive, node-positive tumours. All patients were treated with surgery +/- radiotherapy and adjuvant tamoxifen (30 mg/day) for at least 2 years. TLI, ER, c-erbB-2 and p27kip1 were generally unrelated to each other. PgR was directly related to ER and inversely to c-erbB-2. Tumour size was inversely related to both c-erbB-2 and p27kip1 expression. At a median follow-up of 75 months, 5-year relapse-free survival was significantly lower for patients with very rapidly proliferating (HR = 2.61, 95% CI = 1.34-5.08), PgR negative (HR = 2.76, 95% CI = 1.43-5.33) or relatively low ER content (HR = 2.20, 95% CI = 1.14-4.25) tumours than for patients with tumours expressing the opposite biological profiles. Overall survival was also significantly different as a function of TLI (HR = 3.47, 95% CI = 1.52-7.93) and PgR (HR = 2.27, 95% CI = 1.00-5.15). TLI and PgR maintained an independent relevance in multivariate analysis and together were capable of identifying subgroups of patients at significantly different risk of relapse and death. |
| doi_str_mv | 10.1023/A:1011975510181 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72249873</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72249873</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-928d04e9a2f2a3abffc8069e8c558ff070daecbf5b9e64c5512db77fa618f9053</originalsourceid><addsrcrecordid>eNpdkEtr3DAUhUVoaSaTrrMrIpTs3NHDsqTspkNeMJBNsjayfEWU2NZUkmn776sQQ5uuDhy-ezl8CJ1R8o0SxjfbS0oo1VKIkooeoRUVkleSUfkBrQhtZNUo0hyjk5SeCSFaEv0JHVPaKCUoX6Huuw-jiS8Q8SFC7232YcLBYTv4yVsz4DBnG0bAvtQHiKYbAHcRTMrYmsm-HprsYcoJ51Jn6PFPn59wNmP45R1Mp-ijM0OCz0uu0eP11cPuttrf39zttvvK8lrnSjPVkxq0YY4ZbjrnbFmuQVkhlHNEkt6A7ZzoNDR1KSnrOymdaahymgi-Rhdvfw8x_Jgh5Xb0ycIwmAnCnFrJWK2V5AU8_w98DnOcyraWUVYLRkRdoM0bZGNIKYJrD9EXU79bStpX9-22fee-XHxZ3s7dCP1ffpFdgK8LYFIx62LR59M_HG9EI_gfmkSMeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212452054</pqid></control><display><type>article</type><title>Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>SCARPI, Emanuela ; DE PAOLA, Franca ; SARTI, Manuela ; BAJORKO, Paola ; GRANATO, Anna Maria ; VOLPI, Annalisa ; NANNI, Oriana ; MALTONI, Roberta ; AMADORI, Dino</creator><creatorcontrib>SCARPI, Emanuela ; DE PAOLA, Franca ; SARTI, Manuela ; BAJORKO, Paola ; GRANATO, Anna Maria ; VOLPI, Annalisa ; NANNI, Oriana ; MALTONI, Roberta ; AMADORI, Dino</creatorcontrib><description>The predictivity of tumour size, oestrogen (ER) and progesterone (PgR) receptors, 3H-thymidine labelling index (TLI), c-erbB-2 and p27kip1 expression on clinical outcome was analysed on a consecutive series of 118 postmenopausal patients with ER-positive, node-positive tumours. All patients were treated with surgery +/- radiotherapy and adjuvant tamoxifen (30 mg/day) for at least 2 years. TLI, ER, c-erbB-2 and p27kip1 were generally unrelated to each other. PgR was directly related to ER and inversely to c-erbB-2. Tumour size was inversely related to both c-erbB-2 and p27kip1 expression. At a median follow-up of 75 months, 5-year relapse-free survival was significantly lower for patients with very rapidly proliferating (HR = 2.61, 95% CI = 1.34-5.08), PgR negative (HR = 2.76, 95% CI = 1.43-5.33) or relatively low ER content (HR = 2.20, 95% CI = 1.14-4.25) tumours than for patients with tumours expressing the opposite biological profiles. Overall survival was also significantly different as a function of TLI (HR = 3.47, 95% CI = 1.52-7.93) and PgR (HR = 2.27, 95% CI = 1.00-5.15). TLI and PgR maintained an independent relevance in multivariate analysis and together were capable of identifying subgroups of patients at significantly different risk of relapse and death.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1023/A:1011975510181</identifier><identifier>PMID: 11688513</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Cancer research ; Cancer therapies ; Chemotherapy ; Chemotherapy, Adjuvant ; Clinical outcomes ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Lymph Nodes - pathology ; Mammary gland diseases ; Medical sciences ; Microfilament Proteins - metabolism ; Middle Aged ; Muscle Proteins ; Pharmacology. Drug treatments ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Survival Rate ; Tamoxifen - therapeutic use ; Thymidine - metabolism ; Treatment Outcome ; Tumors</subject><ispartof>Breast cancer research and treatment, 2001-07, Vol.68 (2), p.101-110</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Jul 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c349t-928d04e9a2f2a3abffc8069e8c558ff070daecbf5b9e64c5512db77fa618f9053</citedby><cites>FETCH-LOGICAL-c349t-928d04e9a2f2a3abffc8069e8c558ff070daecbf5b9e64c5512db77fa618f9053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1136565$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11688513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SCARPI, Emanuela</creatorcontrib><creatorcontrib>DE PAOLA, Franca</creatorcontrib><creatorcontrib>SARTI, Manuela</creatorcontrib><creatorcontrib>BAJORKO, Paola</creatorcontrib><creatorcontrib>GRANATO, Anna Maria</creatorcontrib><creatorcontrib>VOLPI, Annalisa</creatorcontrib><creatorcontrib>NANNI, Oriana</creatorcontrib><creatorcontrib>MALTONI, Roberta</creatorcontrib><creatorcontrib>AMADORI, Dino</creatorcontrib><title>Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>The predictivity of tumour size, oestrogen (ER) and progesterone (PgR) receptors, 3H-thymidine labelling index (TLI), c-erbB-2 and p27kip1 expression on clinical outcome was analysed on a consecutive series of 118 postmenopausal patients with ER-positive, node-positive tumours. All patients were treated with surgery +/- radiotherapy and adjuvant tamoxifen (30 mg/day) for at least 2 years. TLI, ER, c-erbB-2 and p27kip1 were generally unrelated to each other. PgR was directly related to ER and inversely to c-erbB-2. Tumour size was inversely related to both c-erbB-2 and p27kip1 expression. At a median follow-up of 75 months, 5-year relapse-free survival was significantly lower for patients with very rapidly proliferating (HR = 2.61, 95% CI = 1.34-5.08), PgR negative (HR = 2.76, 95% CI = 1.43-5.33) or relatively low ER content (HR = 2.20, 95% CI = 1.14-4.25) tumours than for patients with tumours expressing the opposite biological profiles. Overall survival was also significantly different as a function of TLI (HR = 3.47, 95% CI = 1.52-7.93) and PgR (HR = 2.27, 95% CI = 1.00-5.15). TLI and PgR maintained an independent relevance in multivariate analysis and together were capable of identifying subgroups of patients at significantly different risk of relapse and death.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical outcomes</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lymph Nodes - pathology</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Microfilament Proteins - metabolism</subject><subject>Middle Aged</subject><subject>Muscle Proteins</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Survival Rate</subject><subject>Tamoxifen - therapeutic use</subject><subject>Thymidine - metabolism</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkEtr3DAUhUVoaSaTrrMrIpTs3NHDsqTspkNeMJBNsjayfEWU2NZUkmn776sQQ5uuDhy-ezl8CJ1R8o0SxjfbS0oo1VKIkooeoRUVkleSUfkBrQhtZNUo0hyjk5SeCSFaEv0JHVPaKCUoX6Huuw-jiS8Q8SFC7232YcLBYTv4yVsz4DBnG0bAvtQHiKYbAHcRTMrYmsm-HprsYcoJ51Jn6PFPn59wNmP45R1Mp-ijM0OCz0uu0eP11cPuttrf39zttvvK8lrnSjPVkxq0YY4ZbjrnbFmuQVkhlHNEkt6A7ZzoNDR1KSnrOymdaahymgi-Rhdvfw8x_Jgh5Xb0ycIwmAnCnFrJWK2V5AU8_w98DnOcyraWUVYLRkRdoM0bZGNIKYJrD9EXU79bStpX9-22fee-XHxZ3s7dCP1ffpFdgK8LYFIx62LR59M_HG9EI_gfmkSMeg</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>SCARPI, Emanuela</creator><creator>DE PAOLA, Franca</creator><creator>SARTI, Manuela</creator><creator>BAJORKO, Paola</creator><creator>GRANATO, Anna Maria</creator><creator>VOLPI, Annalisa</creator><creator>NANNI, Oriana</creator><creator>MALTONI, Roberta</creator><creator>AMADORI, Dino</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20010701</creationdate><title>Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen</title><author>SCARPI, Emanuela ; DE PAOLA, Franca ; SARTI, Manuela ; BAJORKO, Paola ; GRANATO, Anna Maria ; VOLPI, Annalisa ; NANNI, Oriana ; MALTONI, Roberta ; AMADORI, Dino</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-928d04e9a2f2a3abffc8069e8c558ff070daecbf5b9e64c5512db77fa618f9053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical outcomes</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lymph Nodes - pathology</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Microfilament Proteins - metabolism</topic><topic>Middle Aged</topic><topic>Muscle Proteins</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Survival Rate</topic><topic>Tamoxifen - therapeutic use</topic><topic>Thymidine - metabolism</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SCARPI, Emanuela</creatorcontrib><creatorcontrib>DE PAOLA, Franca</creatorcontrib><creatorcontrib>SARTI, Manuela</creatorcontrib><creatorcontrib>BAJORKO, Paola</creatorcontrib><creatorcontrib>GRANATO, Anna Maria</creatorcontrib><creatorcontrib>VOLPI, Annalisa</creatorcontrib><creatorcontrib>NANNI, Oriana</creatorcontrib><creatorcontrib>MALTONI, Roberta</creatorcontrib><creatorcontrib>AMADORI, Dino</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SCARPI, Emanuela</au><au>DE PAOLA, Franca</au><au>SARTI, Manuela</au><au>BAJORKO, Paola</au><au>GRANATO, Anna Maria</au><au>VOLPI, Annalisa</au><au>NANNI, Oriana</au><au>MALTONI, Roberta</au><au>AMADORI, Dino</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>68</volume><issue>2</issue><spage>101</spage><epage>110</epage><pages>101-110</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The predictivity of tumour size, oestrogen (ER) and progesterone (PgR) receptors, 3H-thymidine labelling index (TLI), c-erbB-2 and p27kip1 expression on clinical outcome was analysed on a consecutive series of 118 postmenopausal patients with ER-positive, node-positive tumours. All patients were treated with surgery +/- radiotherapy and adjuvant tamoxifen (30 mg/day) for at least 2 years. TLI, ER, c-erbB-2 and p27kip1 were generally unrelated to each other. PgR was directly related to ER and inversely to c-erbB-2. Tumour size was inversely related to both c-erbB-2 and p27kip1 expression. At a median follow-up of 75 months, 5-year relapse-free survival was significantly lower for patients with very rapidly proliferating (HR = 2.61, 95% CI = 1.34-5.08), PgR negative (HR = 2.76, 95% CI = 1.43-5.33) or relatively low ER content (HR = 2.20, 95% CI = 1.14-4.25) tumours than for patients with tumours expressing the opposite biological profiles. Overall survival was also significantly different as a function of TLI (HR = 3.47, 95% CI = 1.52-7.93) and PgR (HR = 2.27, 95% CI = 1.00-5.15). TLI and PgR maintained an independent relevance in multivariate analysis and together were capable of identifying subgroups of patients at significantly different risk of relapse and death.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>11688513</pmid><doi>10.1023/A:1011975510181</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2001-07, Vol.68 (2), p.101-110 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72249873 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Cancer research Cancer therapies Chemotherapy Chemotherapy, Adjuvant Clinical outcomes Female Gynecology. Andrology. Obstetrics Humans Lymph Nodes - pathology Mammary gland diseases Medical sciences Microfilament Proteins - metabolism Middle Aged Muscle Proteins Pharmacology. Drug treatments Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Survival Rate Tamoxifen - therapeutic use Thymidine - metabolism Treatment Outcome Tumors |
| title | Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T06%3A32%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarker%20prediction%20of%20clinical%20outcome%20in%20operable%20breast%20cancer%20patients%20treated%20with%20tamoxifen&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=SCARPI,%20Emanuela&rft.date=2001-07-01&rft.volume=68&rft.issue=2&rft.spage=101&rft.epage=110&rft.pages=101-110&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1023/A:1011975510181&rft_dat=%3Cproquest_cross%3E72249873%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212452054&rft_id=info:pmid/11688513&rfr_iscdi=true |